CAR-T therapy has revolutionized cancer treatment, offering a personalized approach that uses genetically modified T cells to target and destroy cancer cells. However, this breakthrough treatment comes at a steep price. In the U.S., CAR-T therapies are priced between $300,000 and $600,000, and when factoring in the costs of treating adverse reactions and hospital stays, the total expenditure can exceed $1,000,000. The high cost makes it inaccessible for many patients and poses a challenge for healthcare systems worldwide.

To address this issue, experts and industry leaders have proposed several strategies to reduce the cost of CAR-T therapy while maintaining its efficacy and accessibility. [Read more…]

Until the first FDA approval of cancer immunotherapy in 1990, the foundations of cancer treatment were surgery, chemotherapy, radiation therapy, and bone marrow transplantation. For more than a decade, immunotherapy has gained worldwide acceptance as the “fifth pillar” of cancer treatment.

Immunotherapy enlists and strengthens the power of a patient’s immune system to attack and kill the cancer cells. Within the human body, T cells are a type of white blood cell that support immunity.  There are 25 million to 1 billion different types of T cells within the human body. These cells fight against anything foreign that enters the human body. [Read more…]